



An Applera Corporation Business
850 Lincoln Centre Drive
Foster City, CA 94404-1128 U.S.A.
www.appliedbiosystems.com

RECEIVED
CENTRAL FAX CENTER

OFFICIAL

FAX TRANSMITTAL

Date: June 17, 2004

To: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Company: U.S. Patent and Trademark Office

Fax No.: 703-872-9306

From: Desi Inocencio for Vincent P. Liptak, Reg. No. 53,225
Legal Department
Fax No.: 650-638-6677
Telephone No.: 650-638-6537
Email: inocenda@applera.com

Subject: Information Disclosure Statement
U.S. Patent Application No. 10/737,509
Filing Date: December 16, 2003
In re Application of: Jeffrey S. Nelson
Title: Reagents for Oligonucleotide Cleavage and Deprotection

Our File: 4688C1

No. of pages (including cover sheet): 7

Message:

Attached is an Information Disclosure Statement for the above-identified patent application. It is believed that no fee is required with this filing. However, the Commissioner is authorized to charge any required fee to Deposit Account No. 01-2213 (Order No. 4688C1).

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 703-872-9306 on June 17, 2004.

Desi Inocencio
Name

Desi Inocencio
Signature

Note: The information contained in this facsimile message may be attorney-client privileged and may contain confidential information intended only for the use of the individual named above, and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify me immediately by telephone (650) 638-6537 and return the original transmission to me by mail without making a copy. Thank you.

OFFICIAL**RECEIVED**

FEDERAL FAX CENTER

Docket No. 4688C1**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of

Jeffrey S. Nelson

Serial No.: 10/737,059

Filed: December 16, 2003

For: **Reagents for Oligonucleotide
Cleavage and Deprotection**

Group Art Unit: To be assigned

Examiner: To be assigned

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being
facsimile transmitted to the United States Patent and
Trademark Office, Fax No. 703-872-9308

June 17, 2004
Date of TransmissionDeji Inocencio
Name of Depositing PartyDeji Inocencio
Signature of Depositing Party**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☐ accompanies a new patent application submitted herewith.
- (b) ☐ is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☒ as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

C:\NrPortbl\image\INOCENDA\68451_1.WPD

- (e) ☐ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**
- (f) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- ☐ Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the items on PTO/SB/08A that are not United States Publications:


- ☐ are supplied herewith
- ☒ are not supplied herewith because they were previously cited by or submitted to the Office in prior application Serial No. 10/091,231, filed March 4, 2002 and relied upon in this application for an earlier filing date under 35 USC §120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: 6/17/04


Vincent P. Liptak, Reg. No. 53,225
Agent for Applicant

Correspondence Address

Customer Number 22896
Applied Biosystems Division
Applera Corporation
850 Lincoln Centre Drive
Foster City, CA 94404
(650) 638-6895 (Phone)
(650) 638-6677 (Fax)

Please type a plus sign (+) inside this box. → ☒

PTO/SB/05A (08-00)
 Approved for use through 10/31/2002. OMB 0661-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/737,059
				Filing Date	December 16, 2003
				First Named Inventor	Jeffrey S. Nelson
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket No.	4688C1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (If known)			
	01	4,965,349		Woo et al.	10-23-1990	
	02	5,514,789		Kempe	05-07-1996	
	03	5,518,651		Reddy Parameswara et al.	05-21-1996	
	04	5,656,741		Chow et al.	08-12-1997	
	05	5,738,829		Kempe	04-14-1998	
	06	5,801,155		Kutyavin et al.	09-01-1998	
	07	5,932,718		Letsinger et al.	08-03-1999	
	08	5,935,527		Andrus et al.	08-10-1999	
	09	5,936,077		Pfleiderer et al.	08-10-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (If known)				
	10	WO	96/03417	A1	Hybridon, Inc.	02-08-1996		
	11	WO	96/32496	A2	Microprobe Corporation	10-17-1996		
	12	EP	0 839 829	A2	Beckman Instruments, Inc.	05-06-1998		
	13	DE	196 27 898	A1	Hoechst AG	01-15-1998		
	14	WO	00/46231	A1	Amersham Pharmacia Biotech, Inc.	08-10-2000		
	15	EP	1 028 124	A2	ISIS Pharmaceuticals Inc.	08-16-2000		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box. ➔ [+]

PTO/SB/08A (08-00)
 Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/737,059
		Filing Date	December 16, 2003
		First Named Inventor	Jeffrey S. Nelson
		Group Art Unit	To be assigned
		Examiner Name	To be assigned
		Attorney Docket No.	4688C1
Sheet	2	of	3

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	AUBERT et al., "Optimized synthesis of phosphorothioate oligodeoxyribonucleotides substituted with a 5'-protected thiol function and a 3'-amino group," <i>Nucleic Acids Research</i> , Vol. 28, No. 3, pp. 818-825 (2000).	
	17	BAIER et al., "Synthesis and Purification in a Single Column on a High-Throughput Automated Oligonucleotide Production System," <i>BioTechniques</i> , Vol. 20, No. 2, pp. 298-303 (February 1996).	
	18	BOAL et al., "Cleavage of oligodeoxyribonucleotides from controlled-pore glass supports and their rapid deprotection by gaseous amines," <i>Nucleic Acids Research</i> , Vol. 24, No. 15, pp. 3115-3117 (1996).	
	19	CHANG et al., "An Improved Deprotection Procedure of Amine-Containing Oligonucleotides from Acrylonitrile Modification," <i>Nucleosides & Nucleotides</i> , 18(6&7), pp. 1205-1206 (1999).	
	20	KUTYAVIN et al., "3'-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures," <i>Nucleic Acids Research</i> , Vol. 28, No. 2, pp. 655-661 (2000).	
	21	MANOHARAN et al., "A New Protecting Group Strategy for Amino Groups in Oligonucleotide Chemistry: CEOC Group," <i>Nucleosides & Nucleotides</i> , 18(6&7), pp. 1199-1201 (1999).	
	22	POLUSHIN et al., "On the rapid deprotection of synthetic oligonucleotides and analogs," <i>Nucleic Acids Research</i> , Vol. 22, No. 4, pp. 639-645 (1994).	
	23	PON et al., "Hydroquinone-O,O'-diacetic acid ("Q-linker") as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis," <i>Nucleic Acids Research</i> , Vol. 25, No. 18, pp. 3629-3635, (1997).	
	24	REDDY et al., "Ultrafast Cleavage and Deprotection of Oligonucleotides Synthesis and Use of C ^{Ac} Derivatives," <i>Nucleosides & Nucleotides</i> , 16(7-9), pp. 1589-1598 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

